How Acetyl-CoA Synthetase Regulates Cellular Metabolism

Acetyl-CoA synthetase is an enzyme that converts free acetate, a simple two-carbon molecule, into acetyl-CoA, the universal fuel and building block that cells use for energy production, fat synthesis, and chemical tagging of DNA-packaging proteins. The enzyme works across virtually all domains of life, from ancient archaea to human neurons, and its roles extend far beyond simple metabolism. Research over the past two decades has linked it to memory formation, tumor survival, fatty liver disease, and the body’s response to alcohol, making it one of the more quietly important enzymes in cell biology.

How the Reaction Works

The chemistry unfolds in two distinct steps, both happening within the same enzyme. First, acetate is combined with ATP to form an intermediate called acetyl-adenylate, releasing pyrophosphate. Second, coenzyme A swaps in and bonds to the acetyl group, producing the final product, acetyl-CoA, and releasing AMP. Structural studies of fungal acetyl-CoA synthetases have captured snapshots of each half-reaction, including the acetyl-adenylate intermediate in both the starting and final configurations of the enzyme.

What makes the machinery unusual is how the enzyme physically rearranges itself between steps. Crystallography of the yeast enzyme revealed that after the first half-reaction, the small C-terminal domain rotates roughly 140 degrees relative to the larger N-terminal domain.¹ This dramatic swivel repositions the active site so coenzyme A can bind and the second thioester-forming reaction can proceed. Kinetic and structural data from mutant enzymes support this “domain alternation” model.² The two-step mechanism is conserved across species, from bacteria to humans, which hints at how ancient and essential this catalytic strategy is.³

Three Family Members With Different Addresses

In mammals, the short-chain acyl-CoA synthetase family includes three members, ACSS1, ACSS2, and ACSS3, and they are not interchangeable. Each lives in a different cellular compartment and handles somewhat different substrates.

ACSS1 resides inside mitochondria. Its primary job is feeding acetate into the tricarboxylic acid cycle for energy production. In nutrient-stressed B-cell lymphomas, ACSS1 is frequently overexpressed and sustains oxidative metabolism by converting acetate to mitochondrial acetyl-CoA, even channeling carbon into the building blocks for DNA and RNA precursors.

ACSS2 is the most studied family member. It was long categorized as a cytosolic enzyme responsible for supplying acetyl-CoA for fat synthesis, but recent work shows it also moves into the nucleus under certain conditions, where it takes on an entirely different role in gene regulation. More on that shortly.

ACSS3 is the least understood of the three. Cloning and characterization of rat ACSS3 showed that it sits in the mitochondrial matrix and actually prefers propionate over acetate as a substrate. Its expression is highest in the liver, followed by the kidney, and fasting significantly increases both the protein level of ACSS3 in the liver and propionyl-CoA synthetase activity in mitochondria.⁴ ACSS3 also appears in the nucleus, where it has been linked to histone propionylation, a chemical mark distinct from the better-known acetylation. In mouse models of high-fat-diet-induced fatty liver disease, ACSS3 generates propionyl-CoA that drives histone propionylation at specific gene promoters, activating genes involved in lipid-related pathways.⁵

How Sirtuins Switch the Enzyme On and Off

The body does not leave acetyl-CoA synthetase running at full throttle all the time. Instead, it uses a clever post-translational switch: attaching or removing an acetyl group from a critical lysine residue on the enzyme itself. When that lysine is acetylated, the enzyme is inactive. Sirtuins, a family of NAD-dependent deacetylases, remove the acetyl tag and reactivate the enzyme.

Of the seven human sirtuins, SIRT1 is the one that reactivates the cytosolic/nuclear ACSS2, while SIRT3 handles the mitochondrial ACSS2 (which is actually ACSS1 in some nomenclatures, since both SIRT1 and SIRT3 showed high catalytic efficiency against the acetylated enzyme in purified-enzyme experiments). The mitochondrial form was completely shut down by acetylation and rapidly brought back to life by SIRT3.⁶ Because sirtuins depend on NAD+, which rises when cells are energy-depleted, this creates a feedback loop: low energy availability boosts NAD+, which activates sirtuins, which reactivate acetyl-CoA synthetase, which then scavenges acetate as an alternative fuel. The system is elegantly tuned to the cell’s metabolic state.

When ACSS2 Moves Into the Nucleus

One of the more surprising discoveries about ACSS2 is that it does not just sit in the cytoplasm making building blocks for fat. Under stress conditions like low oxygen or nutrient scarcity, ACSS2 relocates to the nucleus, where it takes on a gene-regulatory role that has nothing to do with lipid synthesis.

Inside the nucleus, ACSS2 recycles acetate that is released when enzymes strip acetyl groups from histones, the spool-like proteins that package DNA. Normally, that released acetate would diffuse away and be lost. Nuclear ACSS2 captures it and converts it back into acetyl-CoA right at the chromatin, so histone acetyltransferases can immediately reuse it to re-acetylate nearby histones.⁷ This “acetate recycling” mechanism keeps genes accessible for transcription even when the cell is starved of other carbon sources.

The nuclear role goes beyond mere recycling. ACSS2 physically associates with transcription factor EB and travels to the promoter regions of genes involved in autophagy and lysosome production. There, it generates acetyl-CoA on site, fueling histone acetylation that activates those specific genes. This promotes autophagy, cell survival under stress, and, in certain contexts, brain tumor growth.⁸ The dual life of ACSS2, as both a metabolic workhorse and a chromatin-level gene regulator, is part of what makes the enzyme so central to current research.

ACSS2 and Memory

The nuclear gene-regulatory role of ACSS2 has direct consequences for brain function. In 2017, a landmark study showed that ACSS2 binds directly to chromatin at memory-related neuronal genes in the hippocampus, the brain region essential for spatial memory. When researchers reduced ACSS2 levels in the hippocampus of adult mice, the animals developed impaired long-term spatial memory. The affected neurons failed to properly upregulate genes that are normally switched on during memory consolidation, and many of those genes were ones that ACSS2 was already sitting on before the memory-triggering stimulus arrived.⁹

This finding established a direct line between cellular metabolism and cognitive function. The implication is that the brain relies on local acetyl-CoA production at specific stretches of DNA, not just a diffuse pool floating around the nucleus, to flip on the genes it needs for forming durable memories. Whether ACSS2 activity declines with aging or in neurodegenerative disease is an active area of investigation, though solid human data on that front remain limited.

Why Tumors Depend on It

Cancer cells face a metabolic problem: they often grow in oxygen-poor environments deep inside a tumor mass, where the usual pathways for generating acetyl-CoA from glucose are impaired. ACSS2 offers a workaround. Multiple tumor cell lines increase their ACSS2 expression under low-oxygen conditions, with transcript levels rising roughly two- to threefold. When researchers knocked down ACSS2 in those cells, survival under prolonged hypoxia collapsed. After two days without adequate oxygen, cells lacking ACSS2 died en masse, while control cells survived for days longer.¹⁰

In pancreatic cancer cells, hypoxia-driven ACSS2 upregulation has been linked to enhanced proliferation and maintenance of stem-like properties, the capacity of a cancer cell to self-renew and seed new tumors. Knocking ACSS2 down in those cells significantly inhibited both proliferation and stemness.¹¹ These findings have made ACSS2 a target for drug development. A transition-state mimetic inhibitor has already shown the ability to impair breast tumor growth in both cell culture and animal models as a single agent.¹² No ACSS2 inhibitor has reached human clinical trials yet, but the preclinical results are drawing attention.

Sharing the Workload With ATP-Citrate Lyase

ACSS2 is not the only route to cytosolic acetyl-CoA. The other major pathway runs through ATP-citrate lyase (ACLY), which cleaves citrate exported from mitochondria. In healthy, fed conditions, ACLY tends to dominate. But the two enzymes can compensate for each other, and the interplay between them has become a hot topic in metabolic disease research.

In obese mice, selectively depleting either ACSS2 or ACLY from hepatocytes caused a similar roughly 50-percent drop in liver acetyl-CoA levels, demonstrating that both enzymes contribute substantially to the pool that feeds fat synthesis.¹³ That redundancy creates a therapeutic headache: block one pathway, and the other compensates. When researchers knocked down only ACLY in mouse livers on a high-fat, high-fructose diet, the ACSS2-acetate pathway ramped up, actually worsening inflammation and liver injury rather than improving it.¹⁴

Dual inhibition of both ACLY and ACSS2 broke this vicious cycle. It reduced the total flow of acetyl-CoA into fat-building pathways, enhanced fatty acid burning, improved mitochondrial function, and reversed the progression of nonalcoholic fatty liver disease in those mice.¹⁵ A related study found that losing hepatic ACLY alone, or ACLY plus ACSS2 together, unexpectedly worsened fat buildup in a Western-diet model, apparently by suppressing fat-burning gene programs.¹⁶ The takeaway is that the metabolic wiring around acetyl-CoA production is far more tangled than a simple “block the enzyme, fix the problem” model would suggest. Context, diet, and which tissues are targeted all matter enormously.

Muscle Fatigue and Whole-Body Metabolism

ACSS2’s influence extends beyond the liver and brain. In skeletal muscle, ACSS2 contributes to maintaining acetyl-CoA levels that support normal contraction and energy use. Mice engineered to lack ACSS2 globally showed exercise-induced fatigue, and this fatigue worsened when researchers simultaneously blocked ACLY, suggesting that muscle relies on both pathways to keep running smoothly.¹⁷ The work is still early-stage and limited to mouse models, but it raises the possibility that acetyl-CoA supply, not just glucose or fatty acid availability, can be a bottleneck in physical performance.

Alcohol, Iron, and Liver Protection

When you drink alcohol, your liver converts ethanol to acetaldehyde and then to acetate, flooding the organ with the very substrate ACSS2 uses. You might expect this to simply overload the system, but the relationship turns out to be more nuanced. Recent research found that ACSS2 plays a protective role against alcohol-induced liver damage by regulating iron metabolism. Specifically, ACSS2 controls histone acetylation at the promoters of hepcidin genes, which are central regulators of iron balance. In mouse models of alcoholic liver disease, ACSS2 activity helped prevent ferroptosis, a form of cell death driven by iron-dependent lipid damage.¹⁸ This is a case where the nuclear, gene-regulatory face of ACSS2 matters more than its purely metabolic one.

An Ancient Enzyme With Borrowed Origins

Acetyl-CoA synthetase is extraordinarily old. Phylogenetic analysis of the AMP-forming acetyl-CoA synthetase across bacteria, archaea, and eukaryotes found that the eukaryotic gene most likely traces back to the ancestors of mitochondria, the ancient alpha-proteobacteria that were engulfed by an ancestral cell over a billion years ago.¹⁹ In other words, your ACSS genes are likely an inheritance from the same endosymbiotic event that gave your cells their mitochondria in the first place. The enzyme’s deep conservation across life speaks to the fundamental importance of acetate metabolism: any organism that could scavenge acetate and convert it to a usable building block had a survival edge.

The Enzyme in Plants

Acetyl-CoA synthetase also exists in plant plastids, and for decades it was a candidate for the main source of acetyl-CoA used in fatty acid synthesis in seeds. The first plant acetyl-CoA synthetase sequence was cloned from Arabidopsis, revealing a protein with a plastid-targeting sequence.²⁰ However, the timing and location of its gene expression did not match the pattern of lipid accumulation in developing seeds. Instead, the plastidic pyruvate dehydrogenase complex turned out to be the dominant supplier of acetyl-CoA for seed oil production. Biochemical and molecular evidence has converged to show that acetyl-CoA synthetase is not a major source of acetyl-CoA for fatty acid synthesis in leaves or seeds.²¹ So while plants carry the enzyme, they appear to use it for other housekeeping purposes rather than as the main pipeline for making seed oils.

Microbial Engineering Applications

In industrial biotechnology, acetyl-CoA synthetase has found a practical niche. Bacteria like E. coli produce acetate as a wasteful byproduct during glucose fermentation, which is a problem because acetate accumulation inhibits growth and lowers the yield of desired products. Overexpressing acetyl-CoA synthetase in E. coli significantly reduced acetate buildup during fermentation and greatly enhanced the bacteria’s ability to reassimilate acetate when it was the sole carbon source.²² This makes the enzyme a useful tool for metabolic engineers: by recovering wasted carbon and redirecting it into productive pathways, it can improve yields of biofuels, amino acids, and other fermentation products.